Biovail’s Ralivia receives approvable letter

Share this article:
An item appearing in the December issue of Medical Marketing and Media (Pipeline, page 10) incorrectly stated that Biovail's Ralivia ER (tramadol hydrochloride) had received FDA approval.
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters